Compugen is a pioneering company in the field of genomics-based drug and diagnostic discovery. By integrating advanced methodologies from mathematics, computer science, and physics into the realms of biology and organic chemistry, Compugen aims to increase the probability of successful development of novel drug and diagnostic products. The company operates primarily in the immuno-oncology market, focusing on the discovery and development of therapeutic antibodies and immune checkpoint inhibitors. Compugen's core clients include pharmaceutical companies and research institutions seeking innovative solutions for cancer treatment. The business model revolves around the discovery and early-stage development of drug candidates, which are then partnered with larger pharmaceutical companies for further development and commercialization. Compugen generates revenue through research collaborations, licensing agreements, and milestone payments from its partners. The company's innovative pipeline includes first-in-class therapeutic antibodies such as COM701, targeting PVRIG, and COM902, an anti-TIGIT inhibitor, both of which are designed to enhance immune response against cancer.

Keywords: genomics, drug discovery, diagnostics, immuno-oncology, therapeutic antibodies, immune checkpoints, PVRIG, TIGIT, computational biology, biotech partnerships.